Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer.
Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes this simplistic interpretation obtained from experimental models more challenging. Metabolic reprogramming as a function of distinct molecular aberrations has major diagnostic and therapeutic implications.
Departments of Medicine and Medical Oncology; Dana-Farber Cancer Institute; Harvard Medical School ; Boston, MA, USA.
Carmen
C
Priolo
Pathology, Brigham and Women's Hospital, and Medical Oncology; Dana-Farber Cancer Institute; Harvard Medical School ; Boston, MA, USA.
Massimo
M
Loda
AKT signaling; MYC; cancer metabolism; mass spectrometry; prostate cancer